{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jones DA"],"funding":["The Barts Charity Cardiovascular Programme","Heart Research UK","Thomas Godec and Kamran Khan","Translational Research","National Institute for Health Research (NIHR)","Barts Charity Cardiovascular Programme"],"pagination":["1647-1658"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11089333"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["45(18)"],"pubmed_abstract":["Background and aims
Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant proportion of the morbidity and mortality following coronary angiographic procedures in high-risk patients and remains a significant unmet need. In pre-clinical studies inorganic nitrate, which is chemically reduced in vivo to nitric oxide, is renoprotective but this observation is yet to be translated clinically. In this study, the efficacy of inorganic nitrate in the prevention of CIN in high-risk patients presenting with acute coronary syndromes (ACS) is reported.Methods
NITRATE-CIN is a double-blind, randomized, single-centre, placebo-controlled trial assessing efficacy of inorganic nitrate in CIN prevention in at-risk patients p"],"journal":["European heart journal"],"pubmed_title":["Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial."],"pmcid":["PMC11089333"],"funding_grant_id":["MRG00913.","MRG00913","RG2667"],"pubmed_authors":["Wright P","Rathod KS","Jones DA","Andiapen M","Antoniou S","Beirne AM","Parakaw T","Wragg A","Adams J","Yaqoob M","Kelham M","Learoyd A","Wynne L","Ahluwalia A","Khan K","Godec T","Mathur A"],"additional_accession":[]},"is_claimable":false,"name":"Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial.","description":"Background and aims
Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant proportion of the morbidity and mortality following coronary angiographic procedures in high-risk patients and remains a significant unmet need. In pre-clinical studies inorganic nitrate, which is chemically reduced in vivo to nitric oxide, is renoprotective but this observation is yet to be translated clinically. In this study, the efficacy of inorganic nitrate in the prevention of CIN in high-risk patients presenting with acute coronary syndromes (ACS) is reported.Methods
NITRATE-CIN is a double-blind, randomized, single-centre, placebo-controlled trial assessing efficacy of inorganic nitrate in CIN prevention in at-risk patients p","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T17:29:31.239Z","creation":"2026-04-08T14:17:30.65Z"},"accession":"S-EPMC11089333","cross_references":{"pubmed":["38513060"],"doi":["10.1093/eurheartj/ehae100"]}}